
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 12, 2026, 10:00 AM ET
Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
NYSE: $OGNWomen’s Health
OGN Stock Hub: Organon News, Sun Pharma Transaction and Women’s Health
Organon’s September 30, 2026 filing shows a business still generating steady revenue and net income while carrying $8.5 billion of long-term debt. The announced Sun Pharma transaction is a signed, conditional deal, not a completed sale. This article separates reported results from transaction mechanics and examines the women’s health franchise at a high level.
Full research report · PDF
Organon ($OGN), research updated November 21, 2026
17 pages. For personal use only: redistribution prohibited.
Next milestone
The companies expect to complete the merger in early 2027, subject to remaining conditions.
OGN stock at a glance
Chart analysis · JC
Technical chart analysis of $OGN with bull and bear scenarios on JC Just Charts.
Where Organon stands now
Organon reported third-quarter 2026 revenue of $1,574 million and nine-month revenue of $4,592 million, with net income of $418 million for the nine-month period, per the Form 10-Q filed October 30, 2026. The Sun Pharma transaction remains signed but conditional, and closing has not occurred. No closing date has been announced.
Constructive case
Cautious case
Latest Organon news
Nov 12, 2026
Organon presents pooled post-hoc Phase 3 VTAMA data in atopic dermatitis at ACAAI
Organon presented a new analysis of pooled post-hoc Phase 3 data on VTAMA (tapinarof) cream, 1%. The analysis demonstrated consistent efficacy in atopic dermatitis across diverse patient subgroups at ACAAI.
Nov 7, 2026
Real-world evidence on large-scale HADLIMA switch in Veterans Affairs healthcare system
Organon presented new real-world evidence at the American College of Rheumatology (ACR) Annual Meeting. The evidence evaluated a large-scale switch to HADLIMA (adalimumab-bwwd) across the United States Veterans Affairs Healthcare System.
Nov 5, 2026
Tapinarof pediatric plaque psoriasis study marked completed on ClinicalTrials.gov
The ClinicalTrials.gov record for the Phase 3 study Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects (NCT05172726) was updated to COMPLETED on 2026-11-05. The listed completion date is 2026-10-14. Organon and Co. is the lead sponsor, and enrollment is 58.
Nov 5, 2026
Organon to present new analysis of VTAMA (tapinarof) cream, 1% at 2026 allergy meeting
Organon will present new analysis on VTAMA (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Oct 30, 2026
Supplemental financial information with non-GAAP reconciliations for quarter ended September 30, 2026
Organon reported GAAP net income of $164 million and Non-GAAP Adjusted Net Income of $256 million for the quarter ended September 30, 2026. GAAP diluted earnings per share were $0.60, and Non-GAAP Adjusted Diluted Earnings per Share were $0.94. Adjusted EBITDA was $502 million, with an Adjusted EBITDA margin of 31.9%. The Form 10-Q for the quarter was filed with the SEC on October 30, 2026.
Oct 30, 2026
Quarterly dividend declared
The $0.02 dividend is scheduled for December 10, with a November 9 record date. The declaration is separate from completing the pending acquisition.
Catalyst calendar
- Third-quarter 2026 Form 10-Q: filed October 30, 2026
- Sun Pharma transaction: signed, closing conditions pending, date pending
- Full-year 2026 results: date pending
Organon deep dive: the full analysis
The Merlintrader Research Library collects our dated women’s health stock research reports.
01 Reading Organon’s Third Quarter Against the Sun Pharma Headline
Organon’s third-quarter 2026 results, filed October 30, 2026, give a clean baseline against which any transaction outcome must be measured. Revenue was $1,574 million for the quarter and $4,592 million for the nine months ended September 30, 2026, compared with $1,602 million and $4,709 million in the prior-year periods, per the Form 10-Q. Net income was $164 million for the quarter and $418 million for the nine months, with diluted earnings per share of $0.60 and $1.56 respectively. The modest revenue decline alongside stable profitability suggests cost discipline is offsetting top-line pressure.
The balance sheet is the more consequential story. Cash and cash equivalents stood at $1,455 million on September 30, 2026, up from $574 million at December 31, 2025. Long-term debt was $8,485 million, with $69 million in current maturities. The cash build is notable and partly reflects the Jada divestiture, which contributed an $81 million gain within the non-GAAP reconciliation in Exhibit 99.1. That divestiture is a completed transaction and should not be conflated with the Sun Pharma deal, which remains signed but conditional.
Interest expense fell to $325 million for the nine months from $383 million a year earlier, consistent with debt reduction or repricing. The company’s debt stack includes both fixed and floating elements, and the 10-Q’s long-term debt note is the authoritative source for maturity and rate detail. For scenario work, the key company-specific tests are straightforward. First, does adjusted EBITDA margin hold near the 31.4% level implied by the nine-month reconciliation in Exhibit 99.1. Second, does cash conversion remain strong enough to service $8.5 billion of debt without asset sales. Third, does the Sun Pharma transaction close on its stated conditions, and on what timeline.
The distinction between actual sales and transaction proceeds matters. Reported revenue and net income are historical facts. The Sun Pharma transaction is a forward event with signing complete and closing conditional. Financing status for the transaction has not been confirmed as complete as of the latest public filing. Any analysis that treats the deal as closed, or that books proceeds against debt, is premature. The company-specific test is whether operating cash flow and the existing cash balance can carry the capital structure through the closing period without additional dilution or divestiture.
02 How Organon Earns Revenue and Carries Its Debt
Organon operates as a portfolio pharmaceutical company with three reportable segments: women’s health, biosimilars, and established brands. Revenue is generated through product sales across geographies, with the United States and international markets both material. The business model is built on mature, cash-generative products funding a smaller set of growth assets, which is why gross margin and operating expense control drive most of the earnings variability.
For the nine months ended September 30, 2026, GAAP gross margin was 54.4%, and adjusted non-GAAP gross margin was 59.1%, per Exhibit 99.1. The gap reflects manufacturing network costs tied to exiting supply agreements with Merck, stock-based compensation, amortization, and acquisition-related items. Selling, general and administrative expense was $1,279 million on a GAAP basis and $1,188 million adjusted. Research and development was $266 million GAAP and $243 million adjusted. These are lean ratios for a company carrying this debt load, and they explain how $4,592 million of revenue converts to $418 million of net income.
The debt structure is the defining constraint. Long-term debt of $8,485 million against total stockholders’ equity of $1,193 million means leverage is high by any standard. The company’s ability to refinance or repay depends on sustained free cash flow and on the interest rate environment for both fixed and floating exposures. Interest expense of $325 million for nine months annualizes near $433 million, a meaningful claim on earnings before any growth investment.
The Jada divestiture is instructive as a completed precedent. It generated a gain and simplified the portfolio, and the cash proceeds are visible in the higher cash balance. The Sun Pharma transaction, by contrast, is a separate and still-conditional event. Its signing does not change reported debt, cash, or segment revenue. Financing status and closing mechanics remain pending. The business model test is whether the established brands and biosimilars segments can continue funding women’s health investment while the balance sheet deleverages through operating cash flow rather than through assumed deal proceeds.
03 Women’s Health products and sales access
Women’s health is Organon’s most differentiated product franchise and the one most tied to its identity as a standalone company. The portfolio spans contraception, fertility, and related therapeutic areas, and it is the product franchise where the company has the clearest claim to specialized commercial infrastructure. For the nine months ended September 30, 2026, women’s health revenue was $1,362 million, roughly 30% of total revenue, per the segment disclosure in the Form 10-Q.
The clinical evidence base for the contraception franchise is well established at a high level. Peer-reviewed studies of long-acting reversible contraception have examined continuation and tolerability. Madden et al. reported 12-month continuation rates of 81.5% for immediate postabortion etonogestrel implant placement versus 82.8% for interval placement, a statistically similar outcome, in Obstetrics and Gynecology (2012). Vickery et al. found weight change over 12 months varied widely across progestin-only methods, with no adjusted difference between the implant, levonorgestrel intrauterine system, and depot medroxyprogesterone acetate relative to the copper intrauterine device, in Contraception (2013). Silva Dos Santos et al. reached a similar conclusion on body composition over 12 months in Contraception (2017). These observations support the high-level case that continuation and tolerability are competitive attributes, not that any single product dominates.
Access is the commercial translation of that evidence. Organon’s women’s health revenue depends on payer coverage, public health programs, and international tender channels. Sales growth or decline in Note 5 is the cleanest read on whether access is expanding or contracting. The company-specific test is whether women’s health revenue holds above the $1.3 billion nine-month run rate and whether the segment’s margin contribution supports continued investment. The science is settled enough at a high level that the financial question is commercial execution and access, not clinical uncertainty.
04 Biosimilars and Established Brands as the Cash Engine
Biosimilars and established brands are the segments that fund the rest of Organon. Biosimilars revenue for the nine months ended September 30, 2026, was $501 million, and established brands revenue was $2,729 million, per the segment disclosure in the Form 10-Q. Together they represent roughly 70% of total revenue and the bulk of the cash flow that services the debt stack.
The biosimilars portfolio includes products referencing Humira, Remicade, Herceptin, Perjeta, Prolia, and Xgeva, among others, developed with partners including Samsung Bioepis. The economics of biosimilars are characterized by price erosion and competitive intensity, which is why the segment’s revenue trajectory in the 10-Q matters more than any single product. Established brands are mature products with stable but declining revenue, and their value is in cash generation rather than growth.
The financial relevance is direct. With $8,485 million of long-term debt and $325 million of nine-month interest expense, the company depends on these two segments converting revenue into cash. The nine-month cash flow statement in the Form 10-Q is the authoritative source for operating cash flow, and it should be read alongside the cash balance increase to $1,455 million. The Jada divestiture contributed to that increase, so operating cash flow excluding divestiture proceeds is the cleaner measure of the cash engine’s strength.
The company-specific test for these segments is whether established brands decline slower than the cash needs of the balance sheet, and whether biosimilars can offset that decline through volume. The Sun Pharma transaction, if it closes, would alter the portfolio mix, but its terms and financing status are pending and should not be modeled as completed. Until closing, the cash engine is the reported business, and the reported business is what the debt service depends on.
05 Contraceptive Demand and the Comparator Set Organon Actually Competes Against
Organon’s women’s health franchise sits inside a contraceptive market where the unmet need is not efficacy but continuation. The company’s own portfolio spans the etonogestrel implant, the levonorgestrel intrauterine system, and daily methods, and the published evidence base on these products is unusually deep for a commercial portfolio. That evidence matters to the investment case because it speaks to persistence, and persistence is what converts a one-time procedure into a multi-year revenue stream.
The strongest comparator data come from the Contraceptive CHOICE Project. Vickery et al. (Contraception, 2013) followed 427 women over 12 months and found mean weight change of 2.1 kg for etonogestrel implant users, 1.0 kg for the levonorgestrel intrauterine system, 2.2 kg for depot medroxyprogesterone acetate, and 0.2 kg for the copper intrauterine device. In the adjusted model, no difference in weight gain across the progestin-only methods reached significance. Silva Dos Santos et al. (Contraception, 2017) extended this to body composition in 149 women and again found no difference in weight or composition change between the copper device, the levonorgestrel system, and the etonogestrel implant over 12 months. The practical implication is that the most common patient-reported reason for discontinuation is not supported as a differential between Organon’s implant and the non-hormonal comparator. That removes a commercial objection rather than creating one.
Continuation itself is the more decision-relevant metric. Madden et al. (Obstetrics and Gynecology, 2012) compared 141 women receiving the etonogestrel implant immediately postabortion against 935 interval insertions and found 12-month continuation of 81.5% versus 82.8%, a difference that was not statistically significant. Immediate postabortion placement therefore does not degrade persistence, which supports a broader placement window and a larger addressable population than a restrictive label reading would suggest.
The unmet need Organon is actually addressing is access and choice architecture, not clinical superiority. The comparator set is the copper device, depot medroxyprogesterone acetate, and oral methods, and the differentiator is a long-acting reversible option with continuation above 80% at 12 months. For a company carrying $8,485 million of long-term debt as of September 30, 2026, per the Form 10-Q filed October 30, 2026, franchises with multi-year persistence and low price elasticity are the ones that service fixed obligations. The evidence cannot support a head-to-head superiority claim over the copper device on weight outcomes. It establishes equivalence, and equivalence with a long-acting profile is a defensible commercial position.
Peipert et al., Obstetrics & Gynecology 2011 and O’Neil-Callahan et al., Obstetrics & Gynecology 2013 report continuation over different follow-up horizons in the CHOICE cohort. The studies make it possible to discuss persistence separately from initial adoption. Their population and no-cost design limit inference about paid demand in other markets.
06 Official Events Calendar and What the Record Actually Shows
The recent official record for Organon is dominated by two things that must be kept strictly separate: the operating results and the Sun Pharmaceutical transaction. The Form 10-Q filed October 30, 2026 covers the quarterly period ended September 30, 2026 and reports revenues of $1,574 million for the three months then ended, down from $1,602 million a year earlier. Nine-month revenues were $4,592 million against $4,709 million. Net income was $164 million for the quarter and $418 million for the nine months. Those are actual reported figures and they stand on their own.
The same filing shows the balance sheet consequence of prior divestiture activity. Assets held for sale were zero at September 30, 2026, against $8 million of current and $390 million of noncurrent assets held for sale at December 31, 2025. Liabilities held for sale fell from $34 million combined to zero. The Jada divestiture appears in the non-GAAP reconciliation within Exhibit 99.1 filed October 30, 2026 as an $81 million adjustment to GAAP net income for the nine months, excluded from adjusted net income of $674 million. That is a completed disposition, reflected in reported equity, and it is not the Sun transaction.
The Sun Pharmaceutical transaction is a separate matter. The verified record available to this analysis establishes signing and a conditional closing framework, and the parties have not reported closing proceeds, because no closing has been reported. The distinction is material to anyone reading the balance sheet. Cash and cash equivalents of $1,455 million at September 30, 2026 versus $574 million at December 31, 2025 reflect operating cash generation and the completed Jada disposition, not Sun consideration. Long-term debt of $8,485 million and current portion of $69 million are the actual obligations as reported, and they are unaffected by a transaction that has not closed.
The interpretation follows directly. Organon’s reported leverage and liquidity are functions of the business as it stands, and any analysis that folds anticipated Sun proceeds into the September 30, 2026 balance sheet is describing a transaction rather than a reported position. The next announced milestone is the closing of the Sun Pharmaceutical transaction, and its date is pending. Until that closing is disclosed, the fiscal data in the Form 10-Q remain the only verified financial baseline.
07 Reported Period Profit and Loss
The table below reproduces the condensed consolidated statements of income for the three and nine months ended September 30, 2026 and 2025, as filed in the Form 10-Q on October 30, 2026. All amounts are in millions of U.S. dollars except per-share figures.
| Line item | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Revenues | $1,574 | $1,602 | $4,592 | $4,709 |
| Cost of sales | $705 | $745 | $2,093 | $2,137 |
| Gross profit | $869 | $857 | $2,499 | $2,572 |
| Selling, general and administrative | $421 | $415 | $1,279 | $1,288 |
| Research and development | $83 | $84 | $266 | $275 |
| Acquired IPR&D and milestones | $0 | $0 | $1 | $6 |
| Restructuring costs | $0 | $0 | $31 | $88 |
| Interest expense | $106 | $128 | $325 | $383 |
| Exchange losses | $6 | $17 | $15 | $12 |
| Other income, net | ($2) | ($30) | ($69) | ($53) |
| Income before income taxes | $255 | $243 | $651 | $573 |
| Income tax expense | $91 | $83 | $233 | $181 |
| Net income | $164 | $160 | $418 | $392 |
| Diluted earnings per share | $0.60 | $0.61 | $1.56 | $1.50 |
Revenue decreased by $28 million in the quarter and $117 million over nine months. Cost of sales fell $40 million in the quarter, so quarterly gross profit rose $12 million. The nine-month cost decrease of $44 million was smaller than the associated revenue decline, leaving nine-month gross profit down $73 million.
The quality point is that earnings growth in the period came from below the gross profit line. Lower interest cost and lower restructuring charges, $31 million versus $88 million for the nine months, did the work. Revenue was a headwind, not a tailwind. Diluted share count rose to 272,384 thousand in Q3 2026 from 260,653 thousand, which diluted the per-share benefit of the net income increase.
08 Margin Structure, Cost Mix, and Earnings Quality
Gross margin on a GAAP basis was 55.2% in Q3 2026 against 53.5% in Q3 2025, and 54.4% against 54.6% for the nine months, per the Form 10-Q filed October 30, 2026. The adjusted figures in Exhibit 99.1 filed the same date tell a different story. Adjusted non-GAAP gross margin was 59.6% in Q3 2026 against 60.3% a year earlier, and 59.1% against 61.2% for the nine months. The GAAP margin improved while the adjusted margin compressed, and the reconciliation explains why. Manufacturing network costs tied to exiting supply agreements with Merck & Co., Inc. fell to $17 million in Q3 2026 from $39 million, and to $56 million from $101 million for the nine months. Those costs are added back in the adjusted measure, so their decline flatters GAAP and disappears from adjusted. The underlying adjusted margin decline of 2.1 percentage points over nine months is the more informative signal about product mix and price.
The cost mix shows restraint in operating expense and a rising tax burden. Adjusted SG&A was $386 million in Q3 2026 against $394 million, and $1,188 million against $1,198 million for the nine months. Adjusted R&D was flat at $76 million for the quarter and $243 million against $252 million for the nine months. R&D at roughly 5.3% of nine-month revenue is low for a company describing a women’s health growth strategy, and it means the pipeline is being funded at a maintenance level rather than an expansion level.
Earnings quality requires care with the adjustments. Adjusted net income of $674 million for nine months exceeds GAAP net income of $418 million by $256 million, and the largest single bridge item is $215 million of cost of sales adjustments, of which amortization was $141 million. Amortization of acquired intangibles is a real economic cost of the acquisitions that built the portfolio, and excluding it inflates the comparison. The $81 million Jada divestiture gain is excluded from adjusted net income, which is conservative. The $31 million restructuring charge is also excluded, which is less so given that restructuring has recurred across periods.
The balance sheet constrains the margin story. With $8,485 million of long-term debt and $1,193 million of stockholders’ equity at September 30, 2026, interest expense of $325 million for nine months consumes roughly half of the $651 million of pre-tax income. Margin improvement that does not reach the interest line does not reach equity holders.
09 Working Capital and the Balance Sheet as a Read-Through on the Sun Pharma Transaction
The September 30, 2026 balance sheet in Organon’s Form 10-Q shows a company whose working capital profile changed materially during the first nine months of the year, and the changes are best read alongside the announced Sun Pharmaceutical Industries transaction rather than in isolation. Cash and cash equivalents reached $1,455 million at September 30, 2026, up from $574 million at December 31, 2025, a $881 million increase. Accounts receivable rose to $1,480 million from $1,331 million, inventories declined to $1,355 million from $1,406 million, and other current assets increased to $1,079 million from $1,033 million. Total current assets were $5,369 million against total current liabilities of $2,652 million, a current ratio of roughly 2.0. That ratio flatters the position because the current liability line excludes the $8,485 million of long-term debt that sits below it.
Two balance sheet movements deserve separate treatment. First, the assets and liabilities held for sale that appeared at December 31, 2025, $8 million current and $390 million noncurrent on the asset side and $2 million current and $32 million noncurrent on the liability side, are zero at September 30, 2026. The Jada divestiture closed during the nine months, and the supplemental non-GAAP exhibit filed October 30, 2026 records an $81 million gain on that divestiture within the reconciliation of GAAP net income to adjusted net income. Second, accrued and other current liabilities rose to $1,522 million from $1,335 million, a $187 million increase that is large relative to the quarter’s $164 million of net income and warrants attention to the notes rather than assumption.
The Sun Pharma transaction is a signing, not a closing. Organon’s public disclosures describe a conditional transaction, and the September 30, 2026 financial statements contain no closing proceeds, no debt repayment from transaction proceeds, and no discontinued operations presentation tied to it. Readers should therefore treat the $1,455 million cash balance as pre-transaction liquidity, not as evidence of transaction financing. The distinction matters because the cash build coincides with a $325 million interest expense run rate for the nine months and a debt stack that remains fully on balance sheet. Working capital is adequate for the standalone business. It is not a signal about the transaction’s completion or its financing.
Segment disclosure in Note 5 supports a high-level read: women’s health remains a reported product category with its own revenue and cost dynamics, and the portfolio includes established brands and biosimilars licensed from Samsung Bioepis. The balance sheet does not disaggregate working capital by segment, so any claim that women’s health specifically drove the receivables increase would exceed the evidence. What the filing does support is the aggregate direction: receivables up, inventories down, cash up, and held-for-sale balances cleared. Those four facts are the defensible read-through.
10 Cash Flow, Reconciliation, and What the Numbers Do Not Show
The Form 10-Q includes a condensed consolidated statement of cash flows for the nine months ended September 30, 2026, and the supplemental exhibit filed the same day provides the non-GAAP bridge. The table below reconciles the reported GAAP figures to the adjusted measures Organon discloses, using only amounts stated in the filings.
| Measure | Nine months ended September 30, 2026 | Nine months ended September 30, 2025 |
|---|---|---|
| Revenues | $4,592 million | $4,709 million |
| GAAP gross profit | $2,499 million | $2,572 million |
| Adjusted non-GAAP gross profit | $2,714 million | $2,883 million |
| GAAP net income | $418 million | $392 million |
| Non-GAAP adjusted net income | $674 million | $789 million |
| GAAP diluted EPS | $1.56 | $1.50 |
| Interest expense | $325 million | $383 million |
The reconciliation is instructive. GAAP net income rose $26 million year over year while adjusted net income fell $115 million. The gap is explained by the adjustment lines: cost of sales adjustments of $215 million in 2026 versus $311 million in 2025, a $81 million Jada divestiture gain in 2026 with no counterpart, restructuring of $31 million versus $88 million, and a $27 million other expense in 2026 against $37 million of other gain in 2025. The Jada gain is a gain on sale in the income statement but a non-recurring one, and the adjusted figure removes it. Neither number is wrong. They answer different questions.
Interest expense fell to $325 million from $383 million, consistent with the lower debt balance and with the maturity profile disclosed in Note 10. The company generated enough cash to raise the cash balance by $881 million while paying down debt modestly, from $8,644 million combined current and long-term at December 31, 2025 to $8,554 million at September 30, 2026. That combination, cash up and debt down, is the clearest single fact in the cash flow picture.
What the filings do not show is any cash movement attributable to the Sun Pharma transaction. There are no escrowed funds, no bridge financing draw, and no transaction costs of a size that would stand out in the nine-month figures. The cash flow statement is a standalone-business statement. Any analysis that imputes transaction proceeds into the September 30, 2026 liquidity position is unsupported by the primary documents. The next actually announced milestone in the public record is the satisfaction of closing conditions for the Sun Pharma transaction, and its date is pending.
The Jada sale provided $433 million of proceeds reported in investing cash flow. The separate $81 million gain was removed from operating cash flow when reconciling net income to operating cash. September Form 10-Q.
11 Debt, Obligations, and the Terms That Matter
Organon’s debt is the dominant fact in its capital structure, and Note 10 of the Form 10-Q is the primary source. At September 30, 2026, current portion of long-term debt and short-term borrowings was $69 million and long-term debt was $8,485 million, for a combined $8,554 million. At December 31, 2025, the comparable figures were $16 million and $8,628 million, or $8,644 million combined. The net reduction over nine months was $90 million.
| Item | September 30, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of long-term debt and short-term borrowings | $69 million | $16 million |
| Long-term debt | $8,485 million | $8,628 million |
| Combined debt | $8,554 million | $8,644 million |
| Cash and cash equivalents | $1,455 million | $574 million |
| Net debt (combined debt less cash) | $7,099 million | $8,070 million |
The mix between fixed and floating rate debt is disclosed in Note 11 on financial instruments and in the market risk discussion in Item 3. The filing identifies interest rate exposure and the instruments used to manage it. For a reader tracking the Sun Pharma transaction, the relevant point is that the debt remains in place and is serviced from operating cash flow. Interest expense of $325 million for nine months implies an annualized run rate near $433 million, and the year-over-year decline from $383 million to $325 million reflects both lower principal and the rate profile.
The maturity schedule matters more than the total. The $69 million current portion is small relative to $1,455 million of cash, so near-term refinancing risk is not the constraint. The constraint is the longer-dated stack and the covenants and terms attached to it, which the filing describes in Note 10. The Sun Pharma transaction, as announced, is conditional. Until closing conditions are satisfied, the debt terms continue to govern, and the company continues to report interest expense and to disclose compliance. No filing in the record shows a change to the debt terms triggered by the signing. The next actually announced milestone is closing of the Sun Pharma transaction, and its date is pending.
12 Share Issuance, Dilution, and the Equity Base
Share count and equity movements are small in dollar terms but relevant to per-share analysis. At September 30, 2026, issued and outstanding common stock was 262,622 thousand shares, up from 260,316 thousand at December 31, 2025. The cover page of the Form 10-Q states 262,621,584 shares outstanding as of October 23, 2026. Additional paid-in capital rose to $218 million from $167 million, a $51 million increase consistent with stock-based compensation. Retained earnings rose to $1,511 million from $1,109 million, and accumulated other comprehensive loss widened to $539 million from $527 million. Total stockholders’ equity was $1,193 million against $12,208 million of total liabilities, a leverage profile that makes the equity base thin relative to the debt stack.
Dilution is visible in the earnings per share note. Basic weighted average shares were 262,616 thousand for the third quarter of 2026 and diluted weighted average shares were 272,384 thousand, a dilution of roughly 9,768 thousand shares, or about 3.7 percent. For the nine months, basic was 261,874 thousand and diluted was 268,585 thousand. The difference reflects dilutive securities outstanding, and the note to the financial statements identifies the instruments. GAAP diluted EPS of $0.60 for the quarter compares with basic EPS of $0.62, so the dilution cost is two cents per share in the period.
The equity base is the part of the capital structure most exposed to the Sun Pharma transaction’s outcome. A conditional transaction that does not close leaves the current capital structure intact. A transaction that closes on announced terms would change the ownership and financing picture, but the filings do not quantify that change and this analysis does not assume it. What the record does show is modest ongoing issuance through compensation, a thin book equity relative to liabilities, and per-share metrics that already reflect dilution. On women’s health, the peer-reviewed record cited in the filings’ broader evidence base includes continuation and body-composition studies of contraceptive methods, and those support high-level observations about method continuation and tolerability rather than any financial conclusion. The next actually announced milestone remains the closing of the Sun Pharma transaction, and its date is pending.
13 Ownership Concentration and Board Accountability After the Sun Transaction
Organon’s ownership map changed materially during 2026, and the September 30, 2026 quarterly filing is the cleanest place to see it. The company reported 262,621,584 shares outstanding as of October 23, 2026, up from 260,316 thousand at December 31, 2025, with additional paid-in capital rising to $218 million from $167 million. That increase is consistent with equity grants rather than a primary raise, and it matters because the Sun Pharmaceutical transaction is structured as a purchase of shares rather than an issuance of new equity. The 10-Q balance sheet shows no new equity line tied to the deal, and the transaction is described as signing-stage with closing conditions outstanding.
Organon stockholders approved the signed transaction on July 23, 2026. The definitive proxy describes the vote and the original board recommendation.
The merger agreement sets out contractual responsibilities before closing. Ordinary corporate disclosures and the announced progress of the transaction remain the proper basis for assessing governance in the interim.
The remaining transaction timetable depends on the other closing conditions, including regulatory clearances. The completed July vote is distinct from those outstanding conditions.
14 Counterparties, Clinical Evidence and the Limits of What Is Known
The September 10-Q describes the signed and approved acquisition agreement. The stated consideration is $14 per common share, payable in cash if the merger closes. Expected closing is in early 2027, subject to conditions.
The operating counterparties are more legible. Organon’s revenue base is concentrated in established brands licensed or acquired from Merck, and the 10-Q’s product and geographic note shows the portfolio’s dependence on a handful of therapeutic areas. Women’s health is the strategic anchor, and the peer-reviewed record on the etonogestrel implant and the levonorgestrel intrauterine system is the relevant evidence base. Silva Dos Santos et al. (Contraception, 2017) found no difference in weight or body composition change over 12 months among copper IUD, LNG-IUS and etonogestrel implant users in a 149-participant cohort. Vickery et al. (Contraception, 2013) found unadjusted weight gain with the implant versus copper IUD but no difference after adjustment in a 427-participant substudy. Madden et al. (Obstetrics & Gynecology, 2012) reported 12-month continuation of 81.5% for immediate postabortion implant placement versus 82.8% for interval placement, a non-significant difference.
Those findings support a high-level claim only: continuation and tolerability for the implant are comparable to alternatives in the studied populations. They do not establish commercial performance, and they do not speak to Organon’s specific access programs. The 10-Q’s revenue line is the only reported interim evidence of commercial outcomes, and it shows $1,574 million for the quarter ended September 30, 2026, down from $1,602 million a year earlier.
Uncertainty is concentrated in two places. First, the Sun transaction’s conditionality means the counterparty’s financing is unverified. Second, the clinical literature is observational and drawn from a single U.S. cohort study, which limits generalization. Neither gap is resolvable from public filings today.
15 Leverage, Cash Generation and the Execution Gap
Organon’s balance sheet at September 30, 2026 shows $8,485 million of long-term debt and $69 million of current maturities, against $1,455 million of cash and cash equivalents. Net debt is therefore roughly $7,099 million. The 10-Q’s debt note describes both fixed and floating components, and the interest expense line tells the cost: $106 million for the quarter, down from $128 million a year earlier, and $325 million for the nine months, down from $383 million. The decline reflects both rate resets and modest repayment.
Cash generation is the constraint. Nine-month operating cash flow is not separately broken out in the excerpt, but the balance sheet shows retained earnings of $1,511 million, up from $1,109 million, and stockholders’ equity of $1,193 million, up from $752 million. The improvement is real but thin relative to $8.5 billion of debt. Adjusted EBITDA, disclosed in the Exhibit 99.1 supplemental filing, is the metric management uses to frame leverage, and the reconciliation shows adjusted net income of $674 million for the nine months ended September 30, 2026, down from $789 million.
The Jada divestiture is the one completed portfolio action. The supplemental filing shows an $81 million gain in the nine-month period, and the balance sheet shows no remaining held-for-sale assets at September 30, 2026, versus $390 million of noncurrent assets held for sale at December 31, 2025. That is a clean exit, and it removes a small but volatile line.
Execution risk sits in the gap between the restructuring that is finished and the transaction that is not. The $31 million of restructuring costs in the nine months is down sharply, which means the cost program is largely behind the company. But the Sun transaction requires shareholder approval, regulatory clearance and acquirer financing, none of which Organon controls. A failed closing would leave Organon with the same debt load and a lower growth trajectory than the deal implies.
16 What Must Be Measured Before the Next Disclosure
The companies expect closing in early 2027, subject to the outstanding conditions. A specific completion date has not been confirmed.
Revenue trajectory is the first. Third-quarter 2026 revenue of $1,574 million was 1.7% below the prior-year quarter, and nine-month revenue of $4,592 million was 2.5% below. Gross margin improved to 55.2% from 53.5% on a GAAP basis and to 59.6% from 60.3% on an adjusted basis, so the mix is shifting toward higher-margin products even as the top line contracts.
Debt service is the second. Interest expense of $325 million for nine months implies an annualized run rate near $433 million. Any refinancing disclosed in a subsequent filing should be compared against that figure.
Further notices about clearance or definitive completion would narrow the range of possible outcomes. The July shareholder vote is already complete.
Clinical evidence should be read at the portfolio level, not the product level. The contraception literature cited above supports continuation and tolerability claims in studied populations. Patient experience in those studies cannot support a company revenue forecast.
17 How Consideration and Closing Conditions Affect the Transaction Assessment
The merger agreement turns one part of Organon’s investment case into a contractual question. Organon’s September 10-Q describes a cash payment of $14 per common share if the merger closes. That amount is a contractual term rather than a daily price, a valuation for every possible outcome, or an unconditional receivable on the date of the filing. The definitive proxy provides the agreement, the board’s recommendation, and the process that led to the shareholder meeting. Shareholders approved the transaction on July 23. The vote resolved the equity-holder approval condition, while other steps remained in the company’s account of the merger.
A transaction timeline should identify the source of each date. April 26 is the agreement date in Organon’s filing. July 23 represents a completed corporate approval. Early 2027 is the expected closing period stated by the companies and remains a forecast. The acquirer’s October 30 discussion supplies a second public statement about that period. Confirmation would come from a closing announcement or subsequent filing. The elapsed time from negotiations to shareholder approval can inform an understanding of process, but it provides a poor basis for estimating how quickly outstanding conditions will resolve.
The financial review also changes depending on which question the reader is asking. The September accounts remain a history of Organon’s operations. They do not become consolidated Sun Pharma figures while the agreement is pending. Net sales, gross margin, interest expense and financing flows still explain Organon’s ability to operate during the interim period. The purchase consideration informs the potential settlement of existing shares if the transaction closes. The treatment of outstanding debt, the amount of capital required at completion and the acquirer’s funding choices are separate from the sale of the equity and depend on the terms disclosed by the respective parties. Combining the quoted equity consideration with a debt figure from an unrelated date would not explain who carries those obligations between signing and closing.
Risk in the transaction also differs from risk in the portfolio. A change in the regulatory timetable can alter the closing date while leaving clinical demand and net selling prices unchanged. A shortage, price change or reimbursement adjustment for an Organon product can affect its September-to-December operating trajectory without saying whether a closing condition will be satisfied. The merger agreement and established medicines may therefore face different events on the same calendar. The quarterly accounts are the basis for assessing the operating side, while transaction filings document the individual conditions needed to complete the merger.
There is also a distinction between liquidity and earnings while a deal is pending. Organon reported $1.455 billion of cash and equivalents at September 30. Nine-month operating cash flow was $702 million. Those measures reflect different periods and include different activities. The company also recorded an accounting gain on its earlier Jada divestiture. For the interim period, operating cash flow, financing payments and actual access to cash provide better evidence about operational flexibility than the headline gain alone. A reader can follow how these funds move without treating any balance as a committed source for the acquisition.
Subsequent reports can resolve uncertainties in different orders. An announcement that confirms regulatory clearance would narrow the explicit transaction risk. Quarterly operating figures could show whether a change in gross margin or sales was concentrated in a product or geography. A revised closing expectation would change the timetable. These disclosures are most useful when read against what the companies previously said, with completed milestones marked as such and estimated milestones left conditional.
18 Reading Product-Line Sales and Regional Exposure
Organon discloses sales in a form that allows readers to compare major brands and geographies without assuming that these lines have their own operating profit. The September Form 10-Q, Note 5 gives third-quarter Nexplanon and Implanon NXT sales of $200 million globally versus $223 million in the prior-year quarter. U.S. sales were $127 million versus $146 million. The U.S. therefore accounted for $19 million of the $23 million global decline on the reported basis. The remaining countries together accounted for the difference. That arithmetic identifies where a sales change was recorded. It cannot tell how much came from end-user demand, channel orders, net pricing or exchange rates.
The same filing shows a different pattern in fertility. Third-quarter Follistim AQ sales rose from $64 million to $67 million, while nine-month sales declined from $206 million to $188 million. The quarter and the longer period give different signals because the third quarter is only part of the cumulative comparison. A question for the next disclosure is whether the recent improvement is sustained and broad enough to change the nine-month trend. That is distinct from a claim that the business has already returned to growth. NuvaRing had a small decline in the quarter and a small gain on the nine-month basis, another example where the choice of period changes the direction.
The commercial implications of these disclosures depend on portfolio mix. The differences between contraceptive products, fertility products, biosimilars and established brands affect how volumes and revenue change when payer policy evolves or competitors enter. A stable total can conceal changes in individual brands and in the regions where those brands sell. Equally, a group-level gross-margin increase does not demonstrate improved margins in one named product category. The October non-GAAP filing reconciles adjusted measures for the group. It does not allocate that reconciliation across individual brands. The sales table and consolidated earnings statement provide complementary views of the same quarter.
Merlintrader Health Score · $OGN
2.90 out of 5
Assessed November 21, 2026. Merlintrader calculation: 3.00 × 30% + 3.00 × 30% + 3.00 × 20% + 3.00 × 10% + 2.00 × 10% = 2.90 out of 5.
Red flags to track
- Regulatory or other closing conditions could move the expected timetable.
- Regulatory or other closing conditions could move the expected timetable.
- Revenue declined 1.7% year over year in the third quarter of 2026.
- Adjusted net income fell to $674 million from $789 million over nine months.
- Long-term debt of $8,485 million dominates a $13,401 million balance sheet.
- Clinical evidence is observational and drawn from a single U.S. cohort.
OGN Stock FAQ: Organon Questions Answered
What did Organon report for the quarter ended September 30, 2026?
Revenue of $1,574 million, net income of $164 million and diluted earnings per share of $0.60, per the 10-Q filed October 30, 2026.
Is the Sun Pharmaceutical transaction closed?
No. The 10-Q describes a signed agreement with closing conditions outstanding, and no closing date has been disclosed.
How much debt does Organon carry?
$8,485 million of long-term debt and $69 million of current maturities as of September 30, 2026, against $1,455 million of cash.
Did Organon complete any divestiture?
Yes. The Jada divestiture produced an $81 million gain in the nine months ended September 30, 2026, and no held-for-sale assets remain.
What does the clinical literature show about the etonogestrel implant?
Silva Dos Santos et al., Contraception 2017 reported similar changes in body weight and composition across the study groups. In a separate CHOICE analysis, Peipert et al., Obstetrics & Gynecology 2011 examined continuation and satisfaction over twelve months. Neither study measures company sales.
When is the next disclosed milestone?
The companies expect completion in early 2027, subject to remaining conditions.
How many shares are outstanding?
262,621,584 as of October 23, 2026, per the 10-Q cover page.
Is there a disclosed 5% shareholder?
Beneficial ownership is reported separately. An August Schedule 13G discloses a reportable holding, and the April proxy presents holdings on its stated measurement date.
Sources and scientific literature
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $OGN or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Pharmaceutical companies face regulatory, manufacturing, competition, intellectual property, reimbursement, financing and transaction-completion risks. Investors can lose capital. Readers are responsible for their decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



